Corcept Therapeutics is trading at $101.09, down 11.34% in pre-market, with no company announcement identified to explain the decline.
- The company’s latest listed releases were dated September 23 and September 18; no new announcement explaining the October 2 pre-market decline appeared in its release list.
- A report notes a proposed officer share sale but does not establish it as the cause of the move.
- Major indices are higher in the supplied market context.